YM Bio.'b'ser1 News - YMB

Research Update

Research Update YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma - TheraCIM h-R3 (nimotuzumab) Phase II...

Second Quarter Results

YM BioSciences reports second quarter 2005 operational and financial results MISSISSAUGA, ON, Feb. 11 /CNW/ - YM BioSciences Inc. (AMEX:YMI...

Second Quarter Results

Second Quarter Results YM BioSciences reports second quarter 2005 operational and financial results MISSISSAUGA, ON, Feb. 11 /CNW/ - YM...

Research Update

YM BioSciences Expands Development Program for Lead Cancer Drug - YM Partners with Shin Poong Pharmaceutical Co. to Develop Tesmilifene for...

Research Update

Research Update YM BioSciences Expands Development Program for Lead Cancer Drug - YM Partners with Shin Poong Pharmaceutical Co. to Develop...

Research Update

YM BioSciences and Oncoscience Achieve Clinical Milestone - Results Permit Pediatric Brain Cancer Trial to be Converted into Pivotal Randomized...

Research Update

Research Update YM BioSciences and Oncoscience Achieve Clinical Milestone - Results Permit Pediatric Brain Cancer Trial to be Converted...

Research Update

YM BioSciences reports positive EGF-R antibody pivotal Phase II results 90.6% complete responses seen with no evidence of skin toxicity...

Research Update

Research Update YM BioSciences reports positive EGF-R antibody pivotal Phase II results 90.6% complete responses seen with no evidence of...

YM BioSciences Annual and Special Meeting Update

YM BioSciences Annual and Special Meeting Update MISSISSAUGA, ON, Dec. 14 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), is pleased to...

YM BioSciences Annual and Special Meeting Update

YM BioSciences Annual and Special Meeting Update YM BioSciences Annual and Special Meeting Update MISSISSAUGA, ON, Dec. 14 /CNW/ - YM...

Statement re Adoption of Shareholders' Rights Plan

YM BioSciences Adopts Shareholders' Rights Plan MISSISSAUGA, ON, Dec. 3 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer drug...

Statement re Adoption of Shareholders' Rights Plan

Statement re Adoption of Shareholders' Rights Plan YM BioSciences Adopts Shareholders' Rights Plan MISSISSAUGA, ON, Dec. 3 /CNW/ - YM...

Notice of AGM

YM BioSciences Annual Meeting of Shareholders and live audio webcast MISSISSAUGA, ON, Dec. 1 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM...

TheraCIM Granted US Orphan Drug Status

YM BioSciences' TheraCIM Granted US Orphan Drug Status - EGFr antibody receives orphan drug designation from the FDA for treatment of glioma...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

YM Bio.'b'ser1 (YMB)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

YMB News

Research Update

Second Quarter Results

Second Quarter Results

Research Update

Research Update

Research Update

Research Update

Research Update

Research Update

YM BioSciences Annual and Special Meeting Update

YM BioSciences Annual and Special Meeting Update

Statement re Adoption of Shareholders' Rights Plan

Statement re Adoption of Shareholders' Rights Plan

Notice of AGM

TheraCIM Granted US Orphan Drug Status

YMB Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

YM Bio.'b'ser1 (YMB) News

YM Bio.'b'ser1 (YMB)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

YMB News

Research Update

Second Quarter Results

Second Quarter Results

Research Update

Research Update

Research Update

Research Update

Research Update

Research Update

YM BioSciences Annual and Special Meeting Update

YM BioSciences Annual and Special Meeting Update

Statement re Adoption of Shareholders' Rights Plan

Statement re Adoption of Shareholders' Rights Plan

Notice of AGM

TheraCIM Granted US Orphan Drug Status

YMB Discussion

Your Recent History